The business model of Medios AG revolves around providing individualized specialty pharmaceuticals to patients, healthcare professionals, and partners. As a pharmaceutical company, Medios AG specializes in the development and production of patient-specific therapies, making them a key player in personalized medicine. By leveraging their comprehensive knowledge and expertise in pharmaceutical processes, Medios AG ensures that patients receive tailored treatment plans that meet their specific needs. Through partnerships with healthcare professionals and industry experts, Medios AG continuously strives to enhance the quality of patient care and improve therapeutic outcomes.

Medios AG is primarily active in the pharmaceutical and healthcare industries.

The main competitors of Medios AG in the market are XYZ Company, ABC Corporation, and LMN Group.

Medios AG is a German pharmaceutical company founded in 2013. It specializes in the provision of innovative specialty pharmaceuticals and healthcare solutions. Over the years, Medios has established itself as a reliable and trusted partner for hospitals, clinics, and wholesalers in the healthcare industry. The company's focus lies in individualized patient care, particularly in the areas of oncology, neurology, and rare diseases. Medios AG operates with a patient-centric approach, utilizing its comprehensive expertise and strong network to ensure the availability and timely supply of life-saving medications. With its commitment to high-quality standards and commitment to customer satisfaction, Medios AG continues to solidify its position as a leading player in the pharmaceutical sector.

Medios AG, a leading provider of specialty pharmaceuticals and innovative patient-specific solutions, has achieved numerous significant milestones. The company's commitment to innovation and excellence has led to remarkable achievements, including expanding its product portfolio, establishing strategic partnerships, and achieving strong financial growth. Medios AG has successfully entered new markets, launched innovative healthcare programs, and gained recognition for its exceptional customer service. Furthermore, the company's dedication to sustainability and patient-oriented solutions has positioned Medios AG as a trusted leader in the pharmaceutical industry.

Medios AG is primarily present in Germany and its neighboring countries, including Austria and Switzerland. As a leading provider of specialty pharmaceuticals and patient-specific therapies, Medios AG focuses on supplying medicine to specialized pharmacies, hospitals, and clinics in these regions. With its robust infrastructure and extensive network, the company ensures efficient and reliable distribution of pharmaceutical products and personalized medication for patients. Medios AG's presence in these countries and regions allows it to serve the growing need for customized medicine and contribute to better healthcare outcomes for patients.

Medios AG, a renowned pharmaceutical company, embodies a set of values and a distinct corporate philosophy. With a mission to provide comprehensive specialty pharmaceutical services, Medios AG is committed to improving patients' lives through innovative solutions. The company places great importance on maintaining the highest standards of quality, safety, and reliability in its operations. Medios AG embraces a patient-centric approach, ensuring access to vital medications and individualized therapies. By fostering strong partnerships with healthcare professionals and stakeholders, Medios AG strives to contribute to sustainable healthcare systems. Upholding integrity, transparency, and responsibility, Medios AG continually demonstrates its dedication to delivering excellence in the pharmaceutical industry.

Analysts currently set an average price target of 24.48 EUR for the Medios stock (median: 25.50 EUR), implying +102.3 % versus the latest price. The consensus is based on 11 analyst ratings.

Medios Analyst Price Targets 2026

11 analysts currently rate the Medios stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Medios to generate revenue of 2.10 B EUR and earnings per share of 1.40 EUR.

Medios Analyst Price Targets 2026

The Medios share (ILM1.DE) is listed on 9 stock exchanges, including: XETRA (ILM1.DE), Frankfurt (ILM1.F), München (ILM1.MU), Düsseldorf (ILM1.DU), Hamburg (ILM1.HM), London (0QB4.L), London (0QB4.L), SIX (Zürich) (ILM1.SW).

Medios AG is a publicly traded company that specializes in the trading and manufacturing of pharmaceuticals. The company operates as a provider of medication in the specialty pharmacy sector and offers professional solutions for medication supply to its customers. The company divides its offerings into three sectors: Specialty Pharma, Clinical Trial Supply, and Clinical Data Management. Medios focuses on niche markets in the specialty pharmacy sector, particularly in the trading of medications, catering to patients with rare diseases, complex therapeutic forms, and chronic conditions. The company works closely with doctors, health insurance companies, hospitals, and other healthcare providers. Medios guarantees its customers fast delivery of medications, maximum reliability in supply, and optimal customer support with its extensive assortment of pharmaceuticals. In the Clinical Trial Supply sector, Medios functions as a service provider for clinical research, supplying medications to research institutions and making them available for clinical studies as part of drug approvals. Medios relies on digital platforms and processes to ensure efficient and secure processing of orders. Additionally, Medios assists its customers with planning, preparation, and implementation of experiments and other organizational tasks during clinical trials. The Clinical Data Management sector is another important area for Medios, involving the processing of clinical data obtained during clinical studies. Medios provides comprehensive support in the evaluation of research data, utilizing modern IT systems for innovative, transparent, and efficient project processing. Medios adopts a sustainable approach in building relationships with customers and partners, leveraging modern technologies and digital solutions. With its wide-ranging offerings and extensive experience, Medios is regarded as one of the leading providers in the specialty pharmacy sector. The company is expanding both at a national and international level. In summary, Medios holds a leading position in the market as a provider of pharmaceuticals and services in the specialty pharmacy sector. With its diverse offerings, including sectors such as Specialty Pharma, Clinical Trial Supply, and Clinical Data Management, as well as collaboration with customers and partners at national and international levels, the company sets industry standards.

The expected revenue of Medios is 2.10 B EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Medios is 34.26 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Medios is currently 8.93. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medios stock.

The price-to-sales ratio (P/S) of Medios is currently 0.15. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medios stock.

The Eulerpool Quality Score for Medios is 7/10.

The ISIN of Medios is DE000A1MMCC8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Medios is A1MMCC. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Medios is ILM1.DE. The ticker symbol is used to trade Medios shares on the stock exchange.

Medios paid dividends every year for the past 0 years.

Medios is assigned to the 'Health' sector.

The dividends of Medios are distributed in EUR.